title: Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post-stroke period.
abstract: BACKGROUND
  Blood pressure (BP) levels, beat-to-beat blood pressure variability, dynamic cerebral autoregulation and cardiac baroreceptor sensitivity are frequently abnormal following acute stroke and are associated with an adverse short- and long-term prognosis. Thiazide diuretics are effective antihypertensive agents in preventing primary and secondary stroke, but their hypotensive and cerebral autoregulatory effects in the immediate post-stroke period have not been studied.
  
  
  METHODS
  Thirty-seven hypertensive neuroradiologically proven ischaemic stroke patients were randomized in a double-blind, placebo controlled, parallel group study to bendrofluazide 2.5 mg daily or matching placebo, within 96 h of stroke onset, for a 7-day period. Casual and non-invasive beat-to-beat arterial BP levels, cerebral blood flow velocity, ECG and transcutaneous carbon dioxide levels were measured within 70 +/- 20 h of cerebral infarction and again 7 days later. Dynamic cerebral autoregulatory indices, pulse interval, BP variability and cardiac baroreceptor sensitivity were also calculated.
  
  
  RESULTS
  Small, non-significant falls were seen in casual and beat-to-beat BP levels over the 7-day period in both active and placebo-treated patients with no differences between treatments. No significant changes were seen in dynamic cerebral autoregulation or in cardiac baroreceptor sensitivity during the follow-up in either group.
  
  
  CONCLUSIONS
  Following acute ischaemic stroke, the standard dose of bendrofluazide at 2.5 mg daily in this study sample did not lower systemic BP levels over the subsequent 7-day period. There was no evidence that bendrofluazide significantly altered cerebral autoregulation or improved cardiac baroreceptor sensitivity post-ictus. Bendrofluazide appears to be an ineffective hypotensive agent at the standard dosage in the initial post-stroke period.
authors.affiliation: University of Leicester, Department of Cardiovascular Sciences, Ageing and Stroke Medicine Group, The Glenfield Hospital, Leicester, UK.
authors.forename: Penelope J
authors.initials: PJ
authors.lastname: Eames
authors.forename: Thompson G
authors.initials: TG
authors.lastname: Robinson
authors.forename: Ronney B
authors.initials: RB
authors.lastname: Panerai
authors.forename: John F
authors.initials: JF
authors.lastname: Potter
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001539:Bendroflumethiazide / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000188:drug therapy*; D017211:Treatment Failure
chemical_list: D000959:Antihypertensive Agents; D001539:Bendroflumethiazide